Frovatriptan

This MedLibrary.org supplementary page on Frovatriptan is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

Related Sponsors

BM Pharmacy Generic pharmaceuticals at unbeatable prices. Insomnia, men's health, hair health, pain control. bmpharmacy.com
Online Pharmacy Carisoprodol, tadalafil, sildenafil, vardenafil and more... xlpharmacy.com
MedBasket.com Discreet. Inexpensive. Fast shipping. Great selection. What more can we say? medbasket.com
Frugalmed 2000 reasons to shop with us first. frugalmed.com
Ads by Tiva

Frovatriptan
Systematic (IUPAC) name
6-methylamino-6,7,8,9-tetrahydro-
5H-carbazole-3-carboxamide
Identifiers
CAS number 158930-17-7
ATC code N02CC07
PubChem 5284561
DrugBank APRD00270
Chemical data
Formula C14H17N3O 
Mol. mass 243.304 g/mol
Pharmacokinetic data
Bioavailability 20-30%
Metabolism Hepatic
Half life 26 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat.

C: (USA)
B3: (AUS)
Legal status

Prescription only
Routes Oral

Frovatriptan (trade name Frova) is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.[1]

Contents

Pharmacology

Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. It is available as 2.5 mg tablets.

Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than other triptans.

US licensing

Frovatriptan is available only by prescription in the United States, and Canada where a secondary New Drug Approval (sNDA) was filed in July 2006,[2] and which is currently pending. The FDA anticipates completing its review of this application on or before the current PDUFA (Prescription Drug User Fee Act) review date of August 19, 2007. If the sNDA is approved, Frova will be the only medication indicated in the U.S. for the short-term prevention of menstrual migraine (MM).

Footnotes

  1. ^ "Frova". Vernalis. Retrieved on 2007-11-28.
  2. ^ "Patient Information Sheet -- Frovatriptan succinate (marketed as Frova)". Food and Drug Administration (07/2006). Retrieved on 2007-11-28.

External links

v • d • e
Serotonin agonists
5-HT1
5-HT2
5-HT3
5-HT4
v • d • e
Antimigraine preparations (N02C)
Ergot alkaloids
Corticosteroid derivatives
Selective serotonin (5-HT1) agonists
Other antimigraine preparations
Tablets  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Wikipedia content modification information:

  • This page was last modified on 1 October 2008, at 04:03.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Frovatriptan".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.